Senti Biosciences (SNTI) Operating Leases (2021 - 2025)

Senti Biosciences has reported Operating Leases for 5 years, with the latest figure at $23.6 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 18.45% year-over-year to $23.6 million; the trailing twelve-month figure through Dec 2025 stood at $23.6 million (down 18.45% YoY), and the FY2025 full-year result was $23.6 million, down 18.45% from the prior year.
• Operating Leases for Q4 2025 stood at $23.6 million, down from $30.1 million in the prior quarter.
• The five-year high for Operating Leases was $37.2 million in Q3 2023, with the low at $21.0 million in Q4 2021.
• Average Operating Leases over 5 years is $31.9 million, with a median of $32.3 million recorded in 2022.
• Year-over-year, Operating Leases surged 67.25% in 2022 and decreased 18.45% in 2025.
• Tracing SNTI's Operating Leases over 5 years: stood at $21.0 million in 2021, then jumped by 67.25% to $35.1 million in 2022, then slipped by 4.46% to $33.5 million in 2023, then dropped by 13.86% to $28.9 million in 2024, then declined by 18.45% to $23.6 million in 2025.
• The last three Operating Leases figures came in at $23.6 million (Q4 2025), $30.1 million (Q3 2025), and $31.3 million (Q2 2025), per Business Quant data.

Peer Comparison